Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096447 · ClinicalTrials.gov registry record · Phase 2
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00096447: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00096447 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096447, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Interventions
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2004-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096447
The ClinicalTrials.gov registry entry for NCT00096447 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lapatinib ditosylate is the first listed.
NCT00096447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096447 about?
NCT00096447 is a clinical study titled "Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer". This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00096447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2004-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00096447?
The interventions under investigation include: lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00096447?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.